本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Arrowhead Research Corporation

40.08
-1.1850-2.87%
成交量:110.08万
成交额:4,491.66万
市值:55.41亿
市盈率:-35.20
高:41.58
开:41.35
低:39.75
收:41.26
52周最高:43.69
52周最低:9.57
股本:1.38亿
流通股本:1.19亿
量比:0.74
换手率:0.93%
股息:- -
股息率:- -
每股收益(TTM):-1.1384
每股收益(LYR):-5.0048
净资产收益率:-37.11%
总资产收益率:-5.96%
市净率:10.61
市盈率(LYR):-8.01

数据加载中...

公司资料

公司名字:
Arrowhead Research Corporation
交易所:
NASDAQ
成立时间:
2003
员工人数:
609
公司地址:
177 East Colorado Boulevard,Suite 700,Pasadena,California,United States
邮编:
91105
电话:
传真:
626 304 3401
简介:
Arrowhead Pharmaceuticals, Inc.最初于1989年在南达科他州注册成立,后在特拉华州重新注册成立。该公司开发药物,通过沉默疾病的基因来治疗疑难杂症。使用广泛的RNA化学组合和高效的递送模式,该公司的疗法触发RNA干扰机制,以诱导目标基因的快速、深度和持久敲低。该公司已将资源集中于在跨越多个治疗领域的多个动物模型中独家利用其高水平药理活性的疗法。

董事

名称
职位
Christopher Anzalone
Chief Executive Officer, President and Director, Chairman of the Board
Adeoye Olukotun
Independent Director
Hongbo Lu
Independent Director
Mauro Ferrari
Independent Director
Michael S. Perry
Independent Director
Victoria Vakiener
Independent Director
William Waddill
Lead Independent Director
Douglass Ingram
Director

股东

名称
职位
Christopher Anzalone
Chief Executive Officer, President and Director, Chairman of the Board
Patrick O'Brien
Chief Operating Officer and General Counsel
Kenneth A. Myszkowski
Chief Financial Officer
James Hamilton
Chief of Discovery and Translational Medicine